US92686J1060
US92686J1060
Viking Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 393.342.000 | 150.921.000 | 160.6% | |
| Operating Income | -393.342.000 | -150.921.000 | 160.6% |
| Pretax Income | -359.639.000 | -109.963.000 | 227.1% |
| Net Income Common Stockholders | -359.639.000 | -109.963.000 | 227.1% |
| -- | -- | -- | |
| -- | -- | -- |